High-dose chemotherapy in male germ cell cancer patients—a study by the SWENOTECA group
HDCT-treatment according to the SWENOTECA-programme was feasible and associated with promising OS. Early intensification to HDCT for patients with delayed tumour-marker decline during primary-treatment was safe and led to 5-yr OS of 75% with no toxic deaths.
Authors
- Annika Hedlund
- Anna K Jansson (ORCID: https://orcid.org/0000-0001-6305-9729)
- Ingrid Cecilia Glimelius (ORCID: https://orcid.org/0000-0001-6158-3041)
- Torgrim Tandstad (ORCID: https://orcid.org/0000-0002-9786-2138)
- Ása Karlsdóttir (ORCID: https://orcid.org/0000-0001-6434-3537)
- Martin Hellström
- Carl W. Langberg
- Olof Ståhl
- Camilla Sköld
- Gabriella Cohn-Cedermark
- Helene F. S. Negaard
- Hege S. Haugnes
Institutions
- Uppsala University (SE)
- Oslo University Hospital (NO)
- University Hospital of North Norway (NO)
- Karolinska University Hospital (SE)
- Haukeland University Hospital (NO)
- Sahlgrenska University Hospital (SE)
- Karolinska Institutet (SE)
- St Olav's University Hospital (NO)
- Skåne University Hospital (SE)
- UiT The Arctic University of Norway (NO)
- Umeå University (SE)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1038/s41416-025-03322-9
- Primary Topic
- Testicular diseases and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancerfonden
- Uppsala Universitet